Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug combo aims to supercharge immune attack on tough cancers

NCT ID NCT05082259

First seen Feb 14, 2026 · Last updated May 21, 2026 · Updated 11 times

Summary

This early-phase trial tests a new drug (ASTX660) combined with an immunotherapy (pembrolizumab) in people with advanced solid tumors, including triple-negative breast cancer and cervical cancer. The goal is to see if the combination is safe and can help the immune system recognize and kill cancer cells more effectively. About 61 participants will take part across multiple centers.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cambridge University Hospitals NHS Trust

    RECRUITING

    Cambridge, CB2 0QQ, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Royal Marden NHS Foundation Trust - Drug Development Unit

    RECRUITING

    Sutton, SM2 5PT, United Kingdom

    Contact Phone: •••-•••-••••

  • The Royal Marsden NHS Foundation Trust - Breast Unit

    RECRUITING

    Sutton, SM2 5PT, United Kingdom

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.